Dompé Farmaceutici S.p.A [clinicaltrials_resource:a12e3eabcf3f30732b467dd7fc0ed7a7]
clinicaltrials:NCT02001974Safety and Efficacy of rhNGF Eye Drops at Different Doses in Patients With Dry Eye [clinicaltrials:NCT02101281]Two-way Crossover, Single Dose Randomized, Two-stage Bioequivalence of Ketoprofen Lysine Salt Immediate Release vs Granules Oral Solution [clinicaltrials:NCT02350296]clinicaltrials:NCT02370238
collaborator [clinicaltrials_vocabulary:collaborator]
Repertaxin in Prevention of Primary Graft Dysfunction After Lung Transplantation [clinicaltrials:NCT00224406]Reparixin in Prevention of Delayed Graft Dysfunction After Kidney Transplantation [clinicaltrials:NCT00248040]Reparixin in Pancreatic Islet Transplantation [clinicaltrials:NCT01220856]Pilot Efficacy and Safety Study of Oral DF2156A in Patients With Active Bullous Pemphigoid [clinicaltrials:NCT01571895]Study to Evaluate Safety, Tolerability and Pharmacokinetics of rhNGF Eye Drops in Healthy Volunteers [clinicaltrials:NCT01744704]clinicaltrials:NCT01756456clinicaltrials:NCT01817959Pilot Study to Evaluate the Safety and Biological Effects of Orally Administered Reparixin in Early Breast Cancer Patients [clinicaltrials:NCT01861054]Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation [clinicaltrials:NCT01967888]clinicaltrials:NCT02001974Safety and Efficacy of rhNGF Eye Drops at Different Doses in Patients With Dry Eye [clinicaltrials:NCT02101281]A Dose Ranging Study to Evaluate the Safety and Potential Efficacy of rhNGF in Patients With Retinitis Pigmentosa (RP) [clinicaltrials:NCT02110225]Evaluation of Efficacy of 20 µg/ml rhNGF New Formulation (With Anti-oxidant) in Patients With Stage 2 and 3 Neurotrophic Keratitis [clinicaltrials:NCT02227147]Two-way Crossover, Single Dose Randomized, Two-stage Bioequivalence of Ketoprofen Lysine Salt Immediate Release vs Granules Oral Solution [clinicaltrials:NCT02350296]clinicaltrials:NCT02370238Tolerability, Safety and Efficacy of Lubricin (150 µg/ml) Eye Drops Versus Sodium Hyaluronate (HA) 0.18% Eye Drops in Patients With Moderate Dry Eye (DE) [clinicaltrials:NCT02507934]Tolerability, Safety and Efficacy of Lubricin Eye Drops Versus Sodium Hyaluronate Eye Drops in Subjects With Moderate Dry Eye [clinicaltrials:NCT02510235]
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
Repertaxin in Prevention of Primary Graft Dysfunction After Lung Transplantation [clinicaltrials:NCT00224406]Reparixin in Prevention of Delayed Graft Dysfunction After Kidney Transplantation [clinicaltrials:NCT00248040]Reparixin in Pancreatic Islet Transplantation [clinicaltrials:NCT01220856]Pilot Efficacy and Safety Study of Oral DF2156A in Patients With Active Bullous Pemphigoid [clinicaltrials:NCT01571895]Study to Evaluate Safety, Tolerability and Pharmacokinetics of rhNGF Eye Drops in Healthy Volunteers [clinicaltrials:NCT01744704]clinicaltrials:NCT01756456clinicaltrials:NCT01817959Pilot Study to Evaluate the Safety and Biological Effects of Orally Administered Reparixin in Early Breast Cancer Patients [clinicaltrials:NCT01861054]Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation [clinicaltrials:NCT01967888]clinicaltrials:NCT02001974Safety and Efficacy of rhNGF Eye Drops at Different Doses in Patients With Dry Eye [clinicaltrials:NCT02101281]A Dose Ranging Study to Evaluate the Safety and Potential Efficacy of rhNGF in Patients With Retinitis Pigmentosa (RP) [clinicaltrials:NCT02110225]Evaluation of Efficacy of 20 µg/ml rhNGF New Formulation (With Anti-oxidant) in Patients With Stage 2 and 3 Neurotrophic Keratitis [clinicaltrials:NCT02227147]Two-way Crossover, Single Dose Randomized, Two-stage Bioequivalence of Ketoprofen Lysine Salt Immediate Release vs Granules Oral Solution [clinicaltrials:NCT02350296]clinicaltrials:NCT02370238Tolerability, Safety and Efficacy of Lubricin (150 µg/ml) Eye Drops Versus Sodium Hyaluronate (HA) 0.18% Eye Drops in Patients With Moderate Dry Eye (DE) [clinicaltrials:NCT02507934]Tolerability, Safety and Efficacy of Lubricin Eye Drops Versus Sodium Hyaluronate Eye Drops in Subjects With Moderate Dry Eye [clinicaltrials:NCT02510235]
source [clinicaltrials_vocabulary:source]
Dompé Farmaceutici S.p.A [clinicaltrials_resource:a12e3eabcf3f30732b467dd7fc0ed7a7]
Bio2RDF identifier
a12e3eabcf3f30732b467dd7fc0ed7a7
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:a12e3eabcf3f30732b467dd7fc0ed7a7
organization [clinicaltrials_vocabulary:organization]
identifier
clinicaltrials_resource:a12e3eabcf3f30732b467dd7fc0ed7a7
title
Dompé Farmaceutici S.p.A
@en
type
label
Dompé Farmaceutici S.p.A [clinicaltrials_resource:a12e3eabcf3f30732b467dd7fc0ed7a7]
@en